menu
    • menu

    Company profile for CorriXR Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CorriXR Therapeutics is an oncology-focused biotech advancing in vivo gene editing with a proprietary, IP-protected platform. As a spin-out of ChristianaCare and the Gene Editing Institute, we leverage cutting-edge CRISPR/Cas technology and strong collaborations to address critical therapeutic gaps. Our lipid nanoparticle delivery system enables targeted tumor genome editing, improving safety and efficacy while ensuring equita...
    CorriXR Therapeutics is an oncology-focused biotech advancing in vivo gene editing with a proprietary, IP-protected platform. As a spin-out of ChristianaCare and the Gene Editing Institute, we leverage cutting-edge CRISPR/Cas technology and strong collaborations to address critical therapeutic gaps. Our lipid nanoparticle delivery system enables targeted tumor genome editing, improving safety and efficacy while ensuring equitable access for diverse patient communities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CorriXR TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    550 S. College Avenue Suite 107 Newark, DE 19713
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.corrixr.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/corrixrtherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CorriXR Therapeutics Publishes NRF2 Knockout Preclinical Data
    CorriXR Therapeutics Publishes NRF2 Knockout Preclinical Data

    22 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260122023955/en/CorriXR-Therapeutics-Announces-Publication-of-Additional-Preclinical-Data-Corroborating-Ability-of-NRF2-Knockout-to-Restore-Chemosensitivity-in-Solid-Tumors

    BUSINESSWIRE
    22 Jan 2026
    Share Share
    CorriXR, InhaTarget & Merxin Develop Inhaled Lung Cancer Therapy
    CorriXR, InhaTarget & Merxin Develop Inhaled Lung Cancer Therapy

    02 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251202670775/en/CorriXR-Therapeutics-InhaTarget-Therapeutics-and-Merxin-Ltd-Announce-Strategic-Collaboration-for-the-Development-of-Inhaled-Lung-Cancer-Treatment

    BUSINESSWIRE
    02 Dec 2025
    Share Share
    CorriXR Publishes Preclinical Data on CRISPR Against Resistance
    CorriXR Publishes Preclinical Data on CRISPR Against Resistance

    17 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117450095/en/CorriXR-Therapeutics-Announces-Publication-of-Preclinical-Data-Demonstrating-Potential-of-CRISPR-Directed-Gene-Editing-to-Overcome-Drug-Resistance-in-Solid-Tumors

    BUSINESSWIRE
    17 Nov 2025
    Share Share
    CorriXR Therapeutics Secure $1M Investment from State of Delaware
    CorriXR Therapeutics Secure $1M Investment from State of Delaware

    19 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250819018203/en/CorriXR-Therapeutics-Secures-%241M-Investment-from-State-of-Delaware

    BUSINESSWIRE
    19 Aug 2025
    Share Share
    CorriXR Therapeutics Appoints Jan Case as Chief Operating Officer
    CorriXR Therapeutics Appoints Jan Case as Chief Operating Officer

    08 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107177764/en

    BUSINESSWIRE
    08 Jan 2025
    Share Share
    CorriXR Therapeutics Names Eric Kmiec Chief Executive Officer
    CorriXR Therapeutics Names Eric Kmiec Chief Executive Officer

    10 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241210909260/en

    BUSINESSWIRE
    10 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search